Waiting for Permission to Heal: How Prior Authorization Is Leaving Patients Without the Medications They Need
A physician writes a prescription. A patient leaves the clinic with a diagnosis, a treatment plan, and a reasonable expectation that the medication will be in their hands within days. Then the phone calls begin — from the pharmacy, from the insurer, from a prior authorization coordinator buried somewhere in an administrative queue. Days pass. Sometimes weeks. The prescription sits unfilled, and the patient sits waiting.
This is not a rare edge case. It is a structural feature of the American healthcare system that affects tens of millions of patients each year, and its consequences range from uncomfortable to catastrophic.
What Prior Authorization Actually Is — and What It Has Become
Prior authorization, often abbreviated as PA, is a process by which a health insurer requires advance approval before it will cover a prescribed medication or procedure. In theory, the mechanism exists to ensure that treatments are medically appropriate and cost-effective. In practice, it has expanded dramatically in scope, now encompassing thousands of drugs across nearly every therapeutic category.
According to the American Medical Association, physicians complete an average of 45 prior authorization requests per week. Nearly one in four of those requests is ultimately denied. The process consumes an estimated 16 hours of physician and staff time weekly — hours that could otherwise be spent on direct patient care.
For patients, the numbers translate into something more immediate: delayed treatment, worsening symptoms, and, in some cases, irreversible clinical deterioration.
The Gap Between Prescription and Possession
Consider what happens in the interval between a prescription being written and a prior authorization being approved. A patient managing a newly diagnosed autoimmune condition may wait two to three weeks for a biologic medication to clear insurer review. A cancer patient transitioning to an oral chemotherapy agent may find their first cycle delayed while paperwork circulates between oncology offices and insurance administrators. A person with treatment-resistant depression may go without a newly prescribed medication during precisely the period when psychiatric instability poses the greatest risk.
These are not hypothetical scenarios. They are documented patterns. A 2023 survey conducted by the American Cancer Society Cancer Action Network found that 73 percent of patients reported that prior authorization delays had disrupted their care. A substantial portion reported that they had experienced worsening health as a direct result.
The clinical community has a term for what happens when patients go without necessary medications during these intervals: a treatment gap. And treatment gaps, depending on the condition involved, carry consequences that can be difficult or impossible to reverse.
The Administrative Maze Patients Cannot Navigate Alone
One of the less-discussed dimensions of prior authorization is the burden it places on patients themselves. When a pharmacy cannot dispense a medication pending insurer approval, the patient becomes the de facto coordinator of a process they are rarely equipped to manage. They must communicate with their prescribing physician's office, follow up with the insurer's authorization department, understand appeal rights they may not know they have, and do all of this while managing the condition that prompted the prescription in the first place.
For older adults, patients with cognitive or functional limitations, and those without reliable access to transportation or technology, this burden is not merely inconvenient — it is often insurmountable. Research consistently shows that prior authorization processes disproportionately affect patients from lower-income households and communities with fewer healthcare resources, compounding existing disparities in medication access.
Where Home Delivery Services Change the Equation
This is where the model offered by services like MedDelivered begins to demonstrate its structural advantages. Home delivery pharmacies that specialize in coordinating complex prescription fulfillment are not simply moving packages from one location to another. They are operating as active participants in the prior authorization process — tracking approval status, communicating directly with prescribers, and managing the administrative workflow that so frequently stalls at the traditional pharmacy counter.
Because home delivery services maintain dedicated prior authorization teams, they can initiate the approval process earlier in the prescription lifecycle, often before a patient has even left their physician's office. They can monitor insurer timelines, flag delays, and escalate cases that approach clinically significant thresholds. When appeals are necessary, they have the institutional knowledge to pursue them effectively.
For patients managing chronic or complex conditions — the very patients most likely to encounter prior authorization requirements — this coordinated approach can compress the time between prescription and delivery in ways that a traditional retail pharmacy simply cannot replicate. The patient is not left navigating a bureaucratic maze alone; they have a knowledgeable partner working the process on their behalf.
Legislation Is Responding, But Slowly
The prior authorization problem has not gone unnoticed at the policy level. The Improving Seniors' Timely Access to Care Act, which passed the House with overwhelming bipartisan support, seeks to reform the prior authorization process for Medicare Advantage plans by requiring faster turnaround times and greater transparency. Several states have enacted their own prior authorization reform legislation, establishing maximum review windows and requiring real-time decision-making for urgent cases.
These are meaningful steps. But legislation moves slowly, and reform, even when enacted, takes years to filter through the system. In the meantime, patients continue to encounter delays that their physicians have already deemed medically unnecessary.
A System That Asks Patients to Wait When Waiting Has a Cost
The prior authorization system, as currently constructed, operates on an implicit assumption: that the cost of a brief delay is acceptable when weighed against the administrative benefit of insurer review. For some medications and some patients, that assumption may hold. For many others, it does not.
A patient whose blood pressure is uncontrolled, whose blood sugar is elevated, whose psychiatric symptoms are escalating — these are not patients for whom waiting is a neutral act. Every day without medication is a day the underlying condition advances, sometimes in ways that require more intensive and more expensive intervention later.
The irony embedded in the prior authorization process is that the delays it creates can generate precisely the kind of adverse health events that drive up the costs insurers are attempting to manage. Hospitalization, emergency care, and disease progression are not cheap outcomes.
Getting Medications to Patients Faster
At MedDelivered, we believe that the distance between a prescription and a patient should be measured in days, not weeks — and certainly not in administrative obstacles that patients must clear on their own. Our approach to prior authorization is proactive: we engage with insurers early, communicate with prescribers consistently, and keep patients informed at every stage of the process.
For patients who have experienced the frustration of watching a necessary medication sit in limbo while paperwork circulates, the difference a coordinated delivery service makes is not abstract. It is the difference between treatment that begins when it should and treatment that begins when the system finally allows it.
That gap is where health outcomes are won and lost. Closing it is not just a matter of convenience — it is a matter of care.
